Nuvectis Pharma, Inc. (NVCT) Financials

NVCT Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 22.4 million 13.3 million
March 31, 2026 25.4 million 11.2 million
Dec. 31, 2025 31.7 million 13.3 million
Sept. 30, 2025 35.6 million 11.6 million

NVCT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -4.5 million 1.7 million
March 31, 2026 -6.5 million 1.9 million
Dec. 31, 2025 -4.0 million 1.5 million
Sept. 30, 2025 -4.5 million 1.5 million

NVCT Net Income

No data available :(

NVCT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 22.2 million - -
March 31, 2026 25.1 million - -
Dec. 31, 2025 31.6 million - -
Sept. 30, 2025 35.4 million - -

NVCT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 23.5 million
March 31, 2026 23.4 million
Dec. 31, 2025 21.8 million
Sept. 30, 2025 22.7 million

NVCT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 4.7 million 2.5 million -
March 31, 2026 - 4.1 million 2.2 million -
Dec. 31, 2025 - 5.1 million 2.5 million -
Sept. 30, 2025 - 5.8 million 2.0 million -

NVCT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -

NVCT

Price: $23.35

52 week price:
5.55
29.28

Earnings Per Share: -1.32 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 617.4 million

Links: